Comparative deviation of each mutation type from the expected frequency derived from unselected regions of the human genome. Transitions and transversions are shaded and the rejection levels of H 0 beyond which the observed numbers of mutations are deemed significant are represented by black dashed lines. Two-tailed tests were performed using a 5% cutoff to reject H 0 , in which n obs was significantly different from n exp . Critical test values were generated by a short program in Mathematica (Wolfram Research, http://www.wolfram.com/products/mathematica/index.html). The modified conditional rebalancing/reweighting P-value 9 was employed in the calculation of critical values to correct for asymmetry in the binomial distribution.
drug resistance remains a significant clinical problem in CML patients, with amino acid mutations in the BCR-ABL1 TK domain accounting for 60-90% of relapses. 3 Although some mutations result in amino acid changes conferring IM-resistant phenotypes, others have no significant impact on drug efficacy, but may serve as independent prognostic markers of a poor clinical outcome. 3 Primitive (CD34 þ ) CP-CML cells are intrinsically insensitive to IM and genetically unstable. 4 They persist in IM-treated patients and constitute a reservoir from which IM-resistant mutant clones can be generated. BCR-ABL1 TK domain mutations are detected in CD34 þ CP-CML cells before IM treatment, however, the mechanism by which they arise is unknown. 4 In this analysis, we studied sequences from 15 IM-naïve and 316 IM-resistant CP-CML patients and identified a total of 460 somatic point mutations in the BCR-ABL1 TK domain in their leukemic cells. These mutations were non-randomly distributed across the three different codon positions, with very few mutations at codon position 3 (1 of 136 mutations, 0.7%, in IM-naïve patients and 31 of 329, 9%, in IM-resistant patients, Figure 1a ). The remaining mutations were not significantly biased in their distribution over codon positions 1 and 2 in IM-naïve patient cells, whereas in IM-resistant cells, a significant positive bias was observed at codon position 2 (P ¼ 0.042).
On the other hand, BCR-ABL1 TK domain sequences from IM-naïve patient cells had significantly more transitions relative to unselected regions of the human genome across all codon positions (Figure1b and Table 1 ). We also noted a significant positive A-to-G mutational bias (A4G, 1.12 Â 10
À10
) and an under-representation of C-to-T mutations (C4T, 5.34 Â 10 À5 ), when these mutations were compared with unselected regions of the human genome. 5 In addition, we observed a T-to-C mutational hot spot (T4C, 1.23 Â 10 À4 ) at codon position 2. IM-naive cells exhibited a transitional bias at position 2 and overall (1.99 Â 10 À4 , 6.19 Â 10
À5
, respectively; at position 1, P-value ¼ 0.052 as compared with unselected regions of the human genome, Figures 1b and 2a). 5, 6 We observed a similar pattern of BCR-ABL1 TK codon position mutations in sequences derived from IM-resistant cells at position 1 and overall. These included a significant A-to-G bias (A4G, P ¼ 0.011 and 0.006, respectively) and a significant under-representation of C-to-T transitions (C4T, The clinical classification of IM-responders are patients who achieved complete hematologic remission within 3 months, a major cytogenetic remission within 12 months and a complete cytogenetic remission within 18 months. Conversely, IM-resistant patients were patients who did not achieve these response criteria or had evidence of loss of a complete hematologic remission or a complete cytogenetic remission.
Letters to the Editor providing further evidence that the TK domain mutations in CP-CML have a distinct mutational profile.
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Primitive CML cells are characterized by an innate resistance to tyrosine kinase inhibitors (TKIs) and the activity of an unknown mutator that destabilizes their genome and generates somatic point mutations. 4 Our results provide new evidence for the activity of a distinct mutator process in CP-CML. The signature of the mutator comprises an A-to-G transitional bias, A-to-G positional bias with hot spot mutations at codon positions 1 and 2, T-to-C mutations at position 2 and a near lack of position 3 mutations. The clinically observed M244V and D276G mutations result from A-to-G transitions and the F359L mutation arises from T-to-C transitions, both of which would be predicted by the activity of the CML-CP mutator. However, the most clinically important T315I mutation that confers resistance to most currently available TKIs, 7 is generated by a C-to-T transition, suggesting a high mutational rate generating mutational escape around the principal mutator Figure 2 Derivation of mutation frequencies according to mutation type from the number predicted in unselected regions of the human genome. For each codon position from IM-naïve (a) and IM-resistant patients (b), acceptance regions (shaded) are determined by the null hypothesis indicating that the numbers of mutations are expected in the frequencies found in the unselected regions of the human genome. The large dots represent the observed number of mutations and are given for codon positions 1 and 2, and overall.
Letters to the Editor pattern and profound selection. The lack of position 3 mutations is remarkable, as mutations at the third 'wobble' position are least likely to alter amino acid sequences. This implies that the pathogenicity of the mutator may be linked to its ability to introduce changes at codon positions that are most likely to alter the TK amino acid sequence. The mutational signature observed in IM-resistant CP-CML patient cells and in cultured CD34 þ CML cells was similar. This finding suggests that mutant stem/progenitors arise in an IM therapy-independent manner, but give rise to progeny that acquire a growth advantage due to drug selection. The overrepresentation of A-to-T transversions in IM-naïve and -resistant cells is a known feature of gliomas, but not of other solid tumours or other haematological malignancies. Note that the mutations characterized were derived from multiple positions across the BCR-ABL1 TK domain sequence. This makes it unlikely that the observed mutational signature results from the operation of a selection pressure on an as yet undefined primitive CML cell compartment.
It is interesting that the CP-CML mutational signature is strikingly different to that observed in Ph þ B-lymphoid blast crisis, which is characterized by a predominance of G-to-A and C-to-T transitions that are attributed to the activity of activationinduced cytidine deaminase. 8 Activation-induced cytidine deaminase expression was not detected in the CML myeloid cell line (K562) by western blot analysis ( Supplementary  Figure 1) , providing further evidence that the CP-CML mutator is not activation-induced cytidine deaminase and indicating that the transition from CP (myeloid) to blast crisis (B-lymphoid) is accompanied by a switch in the operative mutator.
In addition to providing an insight into the mechanism of somatic point mutation generation in CP-CML, the distinct mutational landscape of the BCR-ABL1 TK domain in primitive CML cells suggests an approach for anticipating emergent TKI resistance. Patients with a predominance of progenitor clones displaying the 'mutator phenotype' are predicted to experience an overall higher frequency of functional resistance to TKI therapy and may consequently benefit from individualized treatment regimens.
In summary, we describe in this study the use of a mathematical model to compare BCR-ABL1 TK domain mutations of IM-naïve CD34 þ cells and IM-resistant cells from a large number of CP-CML patients. This analysis revealed a distinct and non-random pattern of mutations with hot spots in codons 1 and 2 suggesting the activity of a unique mutator in primitive CP-CML cells.
